Biotech Values

[DewDiligence]

Another “Chevron” case—>GLP-1 compounders sue FDA:

https://www.fiercepharma.com/pharma/compounders-sue-fda-removing-eli-lillys-tirzepatide-shortage-list

…last week, when the FDA removed Lilly’s tirzepatide [Zepbound] from its drug shortage list, it erased the compounders’ qualification to manufacture one of their two new cash cows [the other one being semaglutide (Wegovy)].

In response, a compounding industry group has sued the FDA, claiming its action to remove Lilly’s Mounjaro and Zepbound from the shortage list is a “reckless and arbitrary decision—lacking any semblance of lawful process.”